J Clin Endocrinol Metab. 2015;100(9):3486-93.
Radioactive Iodine Therapy Did Not Significantly Increase the Incidence and Recurrence of Subsequent Breast Cancer.
제1저자 안화영, 민혜숙 · 교신저자 박영주, 박수경
소속 (1)
- Departments of Internal Medicine (H.Y.A., J.H.A., H.S.C., B.K., S.-A.I., D.J.P., Y.J.P.), Pathology (H.S.M., I.A.E.), Preventive Medicine (Y.Y., S.H.M., Y.H., S.K.P.), Surgery (D.-Y.N., Y.-K.Y.), and Nuclear Medicine (J.-K.C.), Seoul National University College of Medicine, Seoul, Republic of Korea 110-744; Department of Internal Medicine (H.Y.A.), Seoul National University Bundang Hospital, Seongnam, Republic of Korea 463-707; Department of Internal Medicine (H.Y.A., B.Y.C.), Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 156-755; Department of Biomedical Science (Y.H., S.K.P.), Seoul National University Graduate School, Seoul, Republic of Korea 110-744; Cancer Research Institute (Y.H., D.-Y.N., S.K.P.), Seoul National University, Seoul, Republic of Korea 110-744; and Department of Internal Medicine (H.S.C.), Kangwon National University School of Medicine, Chuncheon, Republic of Korea 200-722.
Abstract
CONTEXT Previous studies on the extent to which radioactive iodine (RAI) therapy for thyroid cancer increases the risk of subsequently developing breast cancer have given conflicting results.
OBJECTIVE This study aimed to evaluate the effect of RAI treatment on breast cancer development and recurrence among female patients with primary thyroid cancer.
DESIGN This was a retrospective cohort study. The risk of subsequent breast cancer associated with RAI and its dose in hazard ratios (HRs) with 95% confidential intervals (CIs) were calculated using time-dependent Cox proportional hazard models.
PATIENTS A total of 6150 patients with thyroid cancer enrolled between 1973 and 2009 were followed until December 2012. Of these, 3631 (59.0%) received RAI therapy. During the follow-up period, 99 primary breast cancers were diagnosed.
MAIN OUTCOME MEASURE Risk of breast cancer development according to RAI therapy and RAI dose during treatment for primary thyroid cancer.
RESULTS RAI therapy did not significantly increase the incidence of subsequent breast cancer among female patients (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.22-1.06) when a 2-year latency period was accounted for. High-dose RAI (≥120 mCi) was associated with a reduced incidence of subsequent breast cancer (HR, 0.17; 95% CI, 0.05-0.62) in the cohort with a 2-year latency period.
CONCLUSIONS The long-term follow-up results of this study suggest that RAI treatment for patients with thyroid cancer may not increase the risk or recurrence of breast cancer.
그 밖의 정보
- 출판 형태
- Journal Article, Research Support, Non-U.S. Gov't
- 저널
- The Journal of clinical endocrinology and metabolism · eISSN 1945-7197
- 전자 출판
- 2015-07-06
- MeSH
- Adult · Breast Neoplasms / epidemiology / etiology · Female · Follow-Up Studies · Humans · Incidence · Iodine Radioisotopes / adverse effects · Middle Aged · Neoplasm Recurrence, Local / epidemiology / etiology · Retrospective Studies · Thyroid Neoplasms / radiotherapy
- Substances
- Iodine Radioisotopes